SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Amgen Drug Meets Primary Endpoint in Late-Stage Study

Amgen’s potential Sjogren’s disease treatment dazodalibep met the primary endpoint in a late-stage study.

AMGN

Related stories